Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by abpagton Apr 18, 2013 1:11am
248 Views
Post# 21268934

1200

1200

Brigus is one of the best

Example

Brigus will need to  cash flow neutral and can fund greyfox and everything at 1275 min

 

2013

 

At 1600 Net cash 26.5 at 95000

At 1275 gives 325 * 95000= 30.875

              Q1. 26 will give production 104

             So extra net cash of 1275*9000=11.475

              So at 1275 net cash off 26,5-30,875+11,475=7.1 milj This will fund g&a plus exploration Net cash flow 0

 

 

2014

Net cash flow off 25 milj makes 10 cent per share at 1275

25 milj less capital needed

 

 

At 1175 will give neg cash off 10 milj 2013 and pos cash flow of 15 mil in 2014 So +/- 1200 is breaking point

 

But at 1200 40% and even more of production will disappear so demand and supply will drive prices quickly a lot above 1200 and with o lot less miners demand for brigus will be good

 

Bullboard Posts